MCID: BSL007
MIFTS: 68

Basal Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Basal Cell Carcinoma

MalaCards integrated aliases for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 12 74 36 29 6 15 17 71
Basal Cell Neoplasm 12 17 71
Basal Cell Cancer 12 54 71
Malignant Basal Cell Tumor 12 71
Experimental Organism Basal Cell Carcinoma 71
Nodulo-Ulcerative Basal Cell Carcinoma 71
Malignant Basal Cell Neoplasm 12
Basal Cell Carcinoma of Skin 12
Epithelioma Basal Cell 12
Neoplasms, Basal Cell 43
Basal Cell Carcinomas 15
Carcinoma Basal Cell 54
Basal Cell Tumor 12
Rodent Ulcer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2513
KEGG 36 H00039
MeSH 43 D018295
UMLS 71 C0007117 C0206710 C0751676 more

Summaries for Basal Cell Carcinoma

KEGG : 36 Cancer of the skin is the most common cancer in Caucasians and basal cell carcinomas (BCC) account for 90% of all skin cancers. The vast majority of BCC cases are sporadic, though there is a rare familial syndrome basal cell nevus syndrome (BCNS, or Gorlin syndrome) that predisposes to development of BCC. In addition, there is strong epidemiological and genetic evidence that demonstrates UV exposure as a risk factor of prime importance. The development of basal cell carcinoma is associated with constitutive activation of sonic hedgehog signaling. The mutations in SMOH, PTCH1, and SHH in BCCs result in continuous activation of target genes. At a cellular level, sonic hedgehog signaling promotes cell proliferation. Mutations in TP53 are also found with high frequency (>50%) in sporadic BCC.

MalaCards based summary : Basal Cell Carcinoma, also known as basal cell neoplasm, is related to basal cell carcinoma 1 and basal cell nevus syndrome. An important gene associated with Basal Cell Carcinoma is SMO (Smoothened, Frizzled Class Receptor), and among its related pathways/superpathways are Basal cell carcinoma and ERK Signaling. The drugs Triamcinolone and Aminolevulinic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and lung, and related phenotypes are digestive/alimentary and embryo

Disease Ontology : 12 A skin carcinoma affecting basal cells.

Wikipedia : 74 Basal-cell carcinoma (BCC), also known as basal-cell cancer, is the most common type of skin cancer. It... more...

Related Diseases for Basal Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 730)
# Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 1 35.8 SMO RASA1 PTCH2 PTCH1 BCC1
2 basal cell nevus syndrome 35.5 TP53 SUFU SMO SHH PTCH2 PTCH1
3 skin carcinoma 33.2 TP53 SUFU SHH PTCH1 GLI2 GLI1
4 focal dermal hypoplasia 32.3 SUFU SHH PTCH2 PTCH1 GLI1
5 medulloblastoma 32.3 TP53 SUFU SMO SHH PTCH2 PTCH1
6 ameloblastoma 32.0 TP53 SMO PTCH1 GLI1 CTNNB1
7 keratocystic odontogenic tumor 31.9 TP53 SUFU SMO SHH PTCH1 GLI1
8 meningioma, familial 31.7 TP53 SUFU SHH RASA1 PTCH1 CTNNB1
9 skin benign neoplasm 31.7 PTCH1 GLI2 GLI1
10 rhabdomyosarcoma 31.5 TP53 SHH PTCH1 GLI1 CTNNB1
11 childhood medulloblastoma 31.2 TP53 SUFU PTCH1 GLI2 CTNNB1
12 cleft palate, isolated 31.2 SHH PTCH1 GLI2 GLI1 CTNNB1
13 pancreatic cancer 31.1 TP53 SMO SHH PTCH1 PALB2 GLI1
14 nodular medulloblastoma 31.1 SUFU SHH PTCH2 PTCH1 GLI2 GLI1
15 embryonal rhabdomyosarcoma 31.0 TP53 PTCH1 GLI1
16 neural tube defects 31.0 TP53 SUFU SHH PTCH1 CTNNB1
17 melanoma, cutaneous malignant 1 30.9 TP53 PALB2 CTNNB1 CDKN2B-AS1
18 polydactyly 30.9 SHH PTCH1 GLI2 GLI1
19 brain cancer 30.9 TP53 SHH PTCH1 GLI1 CTNNB1 BAX
20 brain stem medulloblastoma 30.8 SHH CTNNB1
21 glioma 30.2 TP53 GLI1 CDKN2B-AS1 BAX
22 nodular basal cell carcinoma 12.8
23 basal cell carcinoma, infundibulocystic 12.8
24 basal cell carcinoma 7 12.8
25 pigmented basal cell carcinoma 12.7
26 metatypical basal cell carcinoma 12.7
27 micronodular basal cell carcinoma 12.7
28 anal margin basal cell carcinoma 12.7
29 penis basal cell carcinoma 12.7
30 superficial basal cell carcinoma 12.7
31 morpheaform basal cell carcinoma 12.6
32 basal cell carcinoma, multiple 12.6
33 cystic basal cell carcinoma 12.6
34 adenoid basal cell carcinoma 12.6
35 sarcomatoid basal cell carcinoma 12.6
36 clear cell basal cell carcinoma 12.6
37 basal cell carcinoma 5 12.6
38 basal cell carcinoma 2 12.6
39 basal cell carcinoma 3 12.6
40 basal cell carcinoma 6 12.6
41 vulva basal cell carcinoma 12.6
42 basal cell carcinoma 4 12.6
43 external ear basal cell carcinoma 12.6
44 signet ring basal cell carcinoma 12.6
45 vulvar basal cell carcinoma 12.5
46 infiltrative basal cell carcinoma 12.5
47 scrotum basal cell carcinoma 12.5
48 fibroepithelial basal cell carcinoma 12.5
49 bazex syndrome 12.5
50 follicular basal cell carcinoma 12.4

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to Basal Cell Carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.22 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 RASA1
2 embryo MP:0005380 10.21 CTNNB1 GLI1 GLI2 PALB2 PTCH1 RASA1
3 limbs/digits/tail MP:0005371 10.2 BAX CTNNB1 GLI1 GLI2 PALB2 PTCH1
4 craniofacial MP:0005382 10.19 CTNNB1 GLI1 GLI2 PTCH1 RASA1 SHH
5 nervous system MP:0003631 10.15 BAX CTNNB1 GLI1 GLI2 PALB2 PTCH1
6 integument MP:0010771 10.13 CTNNB1 GLI2 PALB2 PTCH1 PTCH2 SHH
7 hearing/vestibular/ear MP:0005377 10.1 BAX CTNNB1 GLI2 PTCH1 RASA1 SHH
8 muscle MP:0005369 10.09 BAX CTNNB1 GLI2 PTCH1 PTCH2 RASA1
9 neoplasm MP:0002006 10.06 BAX CTNNB1 GLI1 PALB2 PTCH1 PTCH2
10 no phenotypic analysis MP:0003012 9.92 CTNNB1 GLI1 GLI2 PTCH1 RASA1 SHH
11 normal MP:0002873 9.91 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
12 respiratory system MP:0005388 9.81 BAX CTNNB1 GLI1 GLI2 PTCH1 SHH
13 skeleton MP:0005390 9.61 BAX CTNNB1 GLI2 PTCH1 RASA1 SHH
14 vision/eye MP:0005391 9.28 BAX CTNNB1 GLI2 PTCH1 RASA1 SHH

Drugs & Therapeutics for Basal Cell Carcinoma

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Aminolevulinic acid Approved Phase 4 106-60-5 137
3
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
4
Protoporphyrin IX Experimental Phase 4 553-12-8
5 Interferon-alpha Phase 4
6 Tin Fluorides Phase 4
7 triamcinolone acetonide Phase 4
8 Triamcinolone diacetate Phase 4
9 Triamcinolone hexacetonide Phase 4
10 polysaccharide-K Phase 4
11 Pharmaceutical Solutions Phase 4
12 Photosensitizing Agents Phase 4
13 Dermatologic Agents Phase 4
14 Adjuvants, Immunologic Phase 4
15 interferons Phase 4
16 Immunologic Factors Phase 4
17
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
19
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
20
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
21
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
22
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
23
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
24
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Verteporfin Approved, Investigational Phase 3 129497-78-5
27
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
28 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
29
BCG vaccine Investigational Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
31 Antifungal Agents Phase 2, Phase 3
32 Methyl 5-aminolevulinate Phase 3
33 Vaccines Phase 3
34 Antimetabolites Phase 3
35 Analgesics Phase 3
36 Anti-Bacterial Agents Phase 3
37 Antibiotics, Antitubercular Phase 3
38 Tea Phase 2, Phase 3
39 Alkylating Agents Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Muscarinic Agonists Phase 3
43 Cholinergic Agents Phase 3
44 Central Nervous System Stimulants Phase 3
45 Contraceptives, Oral Phase 3
46 Contraceptive Agents Phase 3
47
Megestrol Phase 3 3562-63-8 19090 3080587
48 topoisomerase I inhibitors Phase 3
49 Narcotics Phase 3
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 376)
# Name Status NCT ID Phase Drugs
1 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
2 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
3 Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp Completed NCT00581425 Phase 4
4 Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage Completed NCT00314756 Phase 4 imiquimod
5 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
6 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
7 Thermo-mechanical Fractional Injury Enhances Skin Surface- and Epidermal- Protoporphyrin IX Fluorescence: Comparison of 5-aminolevulinic Acid in Cream and Gel Vehicles Completed NCT04221126 Phase 4 ALA cream;ALA gel
8 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
9 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
10 VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB) Active, not recruiting NCT02436408 Phase 4 Vismodegib
11 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
12 A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control Unknown status NCT00663650 Phase 3
13 An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
14 An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189306 Phase 3 Imiquimod 5% cream
15 Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
16 Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma. Completed NCT00189280 Phase 3 Imiquimod
17 A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
18 A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma. Completed NCT00472043 Phase 3
19 Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage Completed NCT00129519 Phase 3 Imiquimod 5% cream
20 Open Label, Randomized Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma of the Skin Completed NCT01212549 Phase 3
21 A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
22 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
23 Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial. Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
24 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
25 An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
26 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
27 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
28 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
29 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
30 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
31 A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara® (Imiquimod) Cream, 2.5% in Subjects With Actinic Keratoses Completed NCT02120898 Phase 3 Imiquimod;Zyclara®;Vehicle Cream
32 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
33 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
34 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
35 A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma Completed NCT00312000 Phase 3 capecitabine-irinotecan;capecitabine+irinotecan (1st line)
36 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
37 A Randomized, Double Blind, Vehicle-controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Recruiting NCT03573401 Phase 3
38 A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails Recruiting NCT02394132 Phase 3 Imiquimod
39 A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome Active, not recruiting NCT03703310 Phase 3 Patidegib Topical Gel, 2%;Patidegib Topical Gel, Vehicle
40 A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT) Active, not recruiting NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
41 Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
42 A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) Not yet recruiting NCT04308395 Phase 3 Patidegib Topical Gel, 2%
43 A Randomized, Placebo-Controlled, Masked, Multicenter Phase III Study Of Photodynamic Therapy With Verteporfin For Injection (VFI) For The Treatment Of Multiple Basal Cell Carcinoma Terminated NCT00049959 Phase 3 verteporfin PDT
44 A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
45 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
46 Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Unknown status NCT01349361 Phase 2
47 Open, Prospective, Single-center Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma Unknown status NCT03546166 Phase 2 Picato 0.05% Topical Gel
48 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
49 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
50 A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy Unknown status NCT00614809 Phase 2 gefitinib

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fluorouracil

Cochrane evidence based reviews: neoplasms, basal cell

Genetic Tests for Basal Cell Carcinoma

Genetic tests related to Basal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Basal Cell Carcinoma 29

Anatomical Context for Basal Cell Carcinoma

MalaCards organs/tissues related to Basal Cell Carcinoma:

40
Skin, Bone, Lung, Breast, Prostate, Eye, Kidney

Publications for Basal Cell Carcinoma

Articles related to Basal Cell Carcinoma:

(show top 50) (show all 11403)
# Title Authors PMID Year
1
Xeroderma pigmentosum skin: an immune privilege site for tumor development. 61 54
19719835 2010
2
The glutathione-S-transferase P1 polymorphisms correlates with changes in expression of TP53 tumor suppressor in cutaneous basal cell carcinoma. 54 61
19800766 2009
3
[Markers expression of cell proliferation and apoptosis in basal cell carcinoma]. 54 61
20191172 2009
4
Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. 54 61
19797115 2009
5
GLI1 genotypes do not predict basal cell carcinoma risk: a case control study. 54 61
19948058 2009
6
Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. 54 61
19369967 2009
7
The immunoprofile of odontogenic keratocyst (keratocystic odontogenic tumor) that includes expression of PTCH, SMO, GLI-1 and bcl-2 is similar to ameloblastoma but different from odontogenic cysts. 61 54
19473442 2009
8
Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma. 61 54
19298278 2009
9
Correlation and expression of COX-2 and P53 protein in basal cell carcinoma of eyelid. 54 61
19513627 2009
10
Proteinase-activated receptor-2 expression in basal and squamous cell carcinomas compared with normal skin. 61 54
19032384 2009
11
Lack of evidence for activation of the hedgehog pathway in psoriasis. 54 61
18754037 2009
12
Early detection of chromosome 9q22.32q31.1 microdeletion and the nevoid basal cell carcinoma syndrome. 54 61
19233320 2009
13
The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. 61 54
18637131 2009
14
Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. 61 54
19096907 2009
15
Elevated frequency of p53 genetic mutations and AgNOR values in squamous cell carcinoma. 54 61
18715257 2009
16
A novel PTCH1 germline mutation distinguishes basal cell carcinoma from basaloid follicular hamartoma: a case report. 61 54
19203369 2009
17
The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. 61 54
19577853 2009
18
Immunohistochemical galectin-3 expression in non-melanoma skin cancers. 54 61
18951731 2009
19
Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. 54 61
19064570 2008
20
Characteristic overexpression of the forkhead box transcription factor Foxf1 in Patched-associated tumors. 61 54
19020777 2008
21
An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. 61 54
19138009 2008
22
Expression of the hair stem cell-specific marker nestin in epidermal and follicular tumors. 54 61
18693153 2008
23
Prenatal manifestation in a family affected by nevoid basal cell carcinoma syndrome. 61 54
18539553 2008
24
Ultraviolet responses of Gorlin syndrome primary skin cells. 54 61
18510667 2008
25
A novel germ-line mutation of PTCH1 gene in a Japanese family of nevoid basal cell carcinoma syndrome: are the palmoplantar pits associated with true basal cell carcinoma? 54 61
18436435 2008
26
Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma. 61 54
18789069 2008
27
Nonsense-associated altered splicing of the Patched gene fails to suppress carcinogenesis in Gorlin syndrome. 54 61
18476955 2008
28
Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. 54 61
18404670 2008
29
PTCH1 and SMO gene alterations in keratocystic odontogenic tumors. 54 61
18502968 2008
30
Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. 54 61
18264131 2008
31
A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. 54 61
18285427 2008
32
MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. 54 61
18067130 2008
33
Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? 54 61
18190441 2008
34
Microcystic adnexal carcinoma: an immunohistochemical reappraisal. 61 54
18065959 2008
35
Coincident two mutations and one single nucleotide polymorphism of the PTCH1 gene in a family with naevoid basal cell carcinoma syndrome. 54 61
19002359 2008
36
A new mutation of PTCH gene in a Chinese family with nevoid basal cell carcinoma syndrome. 61 54
18272036 2008
37
High-density oligonucleotide array with sub-kilobase resolution reveals breakpoint information of submicroscopic deletions in nevoid basal cell carcinoma syndrome. 54 61
17703323 2007
38
Immunohistochemical comparison of beta-catenin expression by human normal epidermis and epidermal tumors. 61 54
17973813 2007
39
PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. 61 54
17597182 2007
40
Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin. 61 54
17890917 2007
41
Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. 61 54
17596171 2007
42
p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. 61 54
17403527 2007
43
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. 61 54
17316758 2007
44
Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma. 54 61
17448197 2007
45
Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. 54 61
17099730 2007
46
Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. 61 54
17136347 2007
47
Expression of p63 in thymomas and normal thymus. 54 61
17276940 2007
48
Identification of a novel mutation in the PTCH gene in a Korean family with naevoid basal cell carcinoma syndrome. 54 61
16780502 2007
49
Expression of androgen receptor by fibroepithelioma of Pinkus: evidence supporting classification as a basal cell carcinoma variant? 54 61
17284955 2007
50
Polymorphisms in the MTHFR and VDR genes and skin cancer risk. 54 61
16950800 2007

Variations for Basal Cell Carcinoma

ClinVar genetic disease variations for Basal Cell Carcinoma:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NCBI36/hg18 9q22.32-22.33(chr9:95946863-99986314)x1copy number loss Pathogenic 694603
2 SMO NM_005631.5(SMO):c.1417G>C (p.Asp473His)SNV Pathogenic 375938 rs17710891 7:128849189-128849189 7:129209348-129209348
3 PALB2 NM_024675.3(PALB2):c.1451T>A (p.Leu484Ter)SNV Pathogenic/Likely pathogenic 187412 rs786203714 16:23646416-23646416 16:23635095-23635095
4 PTCH1 NM_000264.5(PTCH1):c.3836_3837del (p.Pro1279fs)deletion Uncertain significance 560381 rs1564006281 9:98209701-98209702 9:95447419-95447420

Cosmic variations for Basal Cell Carcinoma:

9 (show top 50) (show all 3424)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149268805 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 12
2 COSM149259613 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 12
3 COSM149268792 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 12
4 COSM149268800 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 12
5 COSM149304906 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 12
6 COSM149331772 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 12
7 COSM149266372 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 12
8 COSM101976974 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 12
9 COSM87040659 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 12
10 COSM87027025 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 12
11 COSM87028684 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 12
12 COSM90144180 TRAF7 skin,NS,carcinoma,basal cell carcinoma c.1802C>T p.T601I 16:2176104-2176104 12
13 COSM88644633 TP63 skin,NS,carcinoma,basal cell carcinoma c.1922C>T p.A641V 3:189894381-189894381 12
14 COSM87925664 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159= 17:7675135-7675135 12
15 COSM87919454 TP53 skin,NS,carcinoma,basal cell carcinoma c.395A>T p.K132M 17:7675217-7675217 12
16 COSM88272290 TP53 skin,NS,carcinoma,basal cell carcinoma c.480G>C p.M160I 17:7675132-7675132 12
17 COSM87898709 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 12
18 COSM87910628 TP53 skin,NS,carcinoma,basal cell carcinoma c.772G>A p.E258K 17:7674191-7674191 12
19 COSM88387703 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 17:7674182-7674182 12
20 COSM87963219 TP53 skin,NS,carcinoma,basal cell carcinoma c.292C>T p.P98S 17:7676077-7676077 12
21 COSM87929396 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 17:7675082-7675082 12
22 COSM87898723 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 17:7673803-7673803 12
23 COSM88310572 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 17:7674286-7674286 12
24 COSM87898714 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 17:7673776-7673776 12
25 COSM87898991 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 17:7675077-7675077 12
26 COSM88408340 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 17:7673721-7673721 12
27 COSM87906968 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 17:7673787-7673787 12
28 COSM87910495 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 17:7673788-7673788 12
29 COSM87899497 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 17:7674945-7674945 12
30 COSM87906130 TP53 skin,NS,carcinoma,basal cell carcinoma c.854A>T p.E285V 17:7673766-7673766 12
31 COSM87919200 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 17:7675101-7675101 12
32 COSM87944274 TP53 skin,NS,carcinoma,basal cell carcinoma c.419C>T p.T140I 17:7675193-7675193 12
33 COSM87921224 TP53 skin,NS,carcinoma,basal cell carcinoma c.835G>A p.G279R 17:7673785-7673785 12
34 COSM87898567 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>T p.P250S 17:7674215-7674215 12
35 COSM87900980 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 17:7673781-7673781 12
36 COSM87947692 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 17:7674193-7674193 12
37 COSM87957813 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 17:7674226-7674226 12
38 COSM87904406 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 17:7673824-7673824 12
39 COSM87917387 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 17:7674217-7674217 12
40 COSM87932688 TP53 skin,NS,carcinoma,basal cell carcinoma c.507G>A p.M169I 17:7675105-7675105 12
41 COSM87903307 TP53 skin,NS,carcinoma,basal cell carcinoma c.841G>A p.D281N 17:7673779-7673779 12
42 COSM87905687 TP53 skin,NS,carcinoma,basal cell carcinoma c.955A>G p.K319E 17:7673573-7673573 12
43 COSM87899661 TP53 skin,NS,carcinoma,basal cell carcinoma c.797G>A p.G266E 17:7673823-7673823 12
44 COSM87908365 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 17:7675158-7675158 12
45 COSM87961406 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 17:7675080-7675080 12
46 COSM87918616 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 12
47 COSM87897745 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 17:7675088-7675088 12
48 COSM87911563 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 17:7675224-7675224 12
49 COSM87922049 TP53 skin,NS,carcinoma,basal cell carcinoma c.713G>T p.C238F 17:7674250-7674250 12
50 COSM87898431 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 17:7675161-7675161 12

Copy number variations for Basal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 256908 9 98205264 98279247 Mutation PTCH Basal cell carcinoma

Expression for Basal Cell Carcinoma

Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for Basal Cell Carcinoma

Pathways related to Basal Cell Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Basal cell carcinoma hsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 TP53 SUFU SMO RASA1 PTCH2 PTCH1
2
Show member pathways
12.91 SUFU SMO PTCH2 PTCH1 GLI2 GLI1
3 12.75 TP53 SUFU SMO SHH PTCH2 PTCH1
4
Show member pathways
12.47 SUFU SMO SHH PTCH1 GLI2 GLI1
5
Show member pathways
12.26 SMO SHH PTCH2 PTCH1
6 12.21 SUFU SHH PTCH2 PTCH1 GLI2 GLI1
7 12.19 TP53 SMO SHH PTCH1 CTNNB1
8 12.08 SMO SHH RASA1 PTCH1
9
Show member pathways
11.97 TP53 SUFU SMO SHH PTCH2 PTCH1
10 11.42 SMO SHH PTCH1 GLI2 GLI1
11 11.4 SUFU SMO SHH PTCH2 PTCH1 GLI2
12 11.38 SUFU SMO SHH PTCH1 GLI2 GLI1
13
Show member pathways
11.24 SMO SHH PTCH2 PTCH1 GLI2
14 11.16 SHH GLI2 GLI1
15
Show member pathways
10.45 SUFU SMO SHH PTCH2 PTCH1 GLI2
16 10.44 SHH PTCH1

GO Terms for Basal Cell Carcinoma

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium GO:0005929 9.55 SUFU SMO PTCH1 GLI2 GLI1
2 ciliary base GO:0097546 9.13 SUFU GLI2 GLI1
3 ciliary tip GO:0097542 8.92 SUFU SMO GLI2 GLI1

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.19 TP53 SUFU SMO SHH PTCH1 GLI2
2 positive regulation of cell proliferation GO:0008284 10.14 SMO SHH GLI2 GLI1 CTNNB1
3 positive regulation of transcription, DNA-templated GO:0045893 10.14 TP53 SMO SHH PTCH1 GLI2 GLI1
4 positive regulation of gene expression GO:0010628 10.13 TP53 SMO SHH CTNNB1 CDKN2B-AS1
5 negative regulation of gene expression GO:0010629 10.08 TP53 SMO SHH CTNNB1 CDKN2B-AS1
6 negative regulation of apoptotic process GO:0043066 10.08 TP53 SMO SHH RASA1 PALB2 GLI2
7 heart development GO:0007507 10.03 TP53 SHH GLI2 CTNNB1
8 regulation of cell proliferation GO:0042127 10.02 TP53 SHH PTCH1 CTNNB1
9 in utero embryonic development GO:0001701 9.99 TP53 SMO PTCH1 PALB2 GLI2 CTNNB1
10 kidney development GO:0001822 9.95 SHH GLI2 CTNNB1 BAX
11 lung development GO:0030324 9.92 SHH GLI2 GLI1 CTNNB1
12 multicellular organism growth GO:0035264 9.91 TP53 SMO PALB2
13 determination of left/right symmetry GO:0007368 9.91 SUFU SMO SHH
14 canonical Wnt signaling pathway GO:0060070 9.9 SHH GLI1 CTNNB1
15 heart looping GO:0001947 9.89 SUFU SMO SHH
16 embryonic digit morphogenesis GO:0042733 9.88 SHH GLI2 CTNNB1
17 positive regulation of neuron apoptotic process GO:0043525 9.88 TP53 CTNNB1 BAX
18 vasculogenesis GO:0001570 9.88 SMO SHH RASA1 CTNNB1
19 branching involved in ureteric bud morphogenesis GO:0001658 9.87 SHH PTCH1 CTNNB1
20 positive regulation of smoothened signaling pathway GO:0045880 9.86 SMO SHH GLI1
21 cell fate specification GO:0001708 9.86 SMO SHH CTNNB1
22 pattern specification process GO:0007389 9.85 SMO SHH PTCH1 GLI2
23 T cell differentiation in thymus GO:0033077 9.83 TP53 SHH CTNNB1
24 skin development GO:0043588 9.83 SUFU SHH PTCH2 CTNNB1
25 developmental growth GO:0048589 9.82 SMO SHH GLI2
26 proximal/distal pattern formation GO:0009954 9.81 GLI2 GLI1 CTNNB1
27 positive regulation of mesenchymal cell proliferation GO:0002053 9.8 SMO SHH CTNNB1
28 spinal cord motor neuron differentiation GO:0021522 9.79 SHH PTCH1 GLI2
29 positive regulation of neuroblast proliferation GO:0002052 9.79 SMO SHH CTNNB1
30 hindbrain development GO:0030902 9.78 SHH GLI2 CTNNB1
31 hair follicle morphogenesis GO:0031069 9.78 SMO SHH GLI2 CTNNB1
32 cell fate determination GO:0001709 9.77 PTCH2 PTCH1 CTNNB1
33 odontogenesis of dentin-containing tooth GO:0042475 9.77 SMO SHH GLI2 CTNNB1 BAX
34 somite development GO:0061053 9.76 SMO SHH PTCH1
35 negative regulation of smoothened signaling pathway GO:0045879 9.76 SUFU PTCH2 PTCH1 GLI2
36 digestive tract morphogenesis GO:0048546 9.75 SHH GLI1
37 regulation of osteoblast differentiation GO:0045667 9.74 GLI1 CTNNB1
38 mammary gland epithelial cell differentiation GO:0060644 9.74 SMO PTCH1
39 ectoderm development GO:0007398 9.74 SHH CTNNB1
40 thalamus development GO:0021794 9.74 SMO SHH
41 commissural neuron axon guidance GO:0071679 9.74 SMO PTCH1
42 smooth muscle tissue development GO:0048745 9.74 SMO SHH PTCH1
43 metanephric collecting duct development GO:0072205 9.73 SHH PTCH1
44 positive regulation of T cell differentiation in thymus GO:0033089 9.73 SHH GLI2
45 response to salt stress GO:0009651 9.73 TP53 BAX
46 prostate gland development GO:0030850 9.73 SHH PTCH1 GLI1
47 lung-associated mesenchyme development GO:0060484 9.72 SHH CTNNB1
48 embryonic foregut morphogenesis GO:0048617 9.72 SHH CTNNB1
49 positive regulation of skeletal muscle tissue development GO:0048643 9.71 SHH CTNNB1
50 positive regulation of epidermal cell differentiation GO:0045606 9.71 PTCH2 PTCH1

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hedgehog family protein binding GO:0097108 9.26 PTCH2 PTCH1
2 hedgehog receptor activity GO:0008158 9.16 PTCH2 PTCH1
3 smoothened binding GO:0005119 8.96 PTCH2 PTCH1
4 patched binding GO:0005113 8.8 SMO SHH PTCH1

Sources for Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....